Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients

被引：119

作者：

Janus, N. ^{[1
]}

Thariat, J. ^{[2
]}

Boulanger, H. ^{[3
]}

Deray, G. ^{[1
]}

Launay-Vacher, V. ^{[1
]}

机构：

[1] Hop La Pitie Salpetriere, Dept Nephrol, ICAR, F-75013 Paris, France

[2] Univ Nice Sophia Antipolis, Ctr Antoine Lacassagne, Dept Radiat Oncol, Nice, France

[3] Clin Estree, Dept Nephrol & Dialysis, Stains, France

来源：

ANNALS OF ONCOLOGY | 2010年 / 21卷 / 07期

关键词：

cytotoxic drugs; dosing recommendations; hemodialysis; pharmacokinetics; LOW-DOSE METHOTREXATE; CHRONIC-RENAL-FAILURE; METASTATIC COLORECTAL-CANCER; ADVANCED OVARIAN-CANCER; MAGNETIC-RESONANCE-SPECTROSCOPY; HIGH-FLUX HEMODIALYSIS; CELL LUNG-CANCER; PHARMACOKINETIC ANALYSIS; COMBINATION CHEMOTHERAPY; CLINICAL PHARMACOKINETICS;

D O I：

10.1093/annonc/mdp598

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Methods: We reviewed the international literature on the pharmacokinetics, efficacy, tolerance and dosage adjustment of cytotoxic drugs used to treat solid tumor patients and when available, specific literature on HD cancer patients. Results: From these data, dosing recommendations are given for the most prescribed cytotoxic drugs in clinical practice. Conclusions: Dosage adjustments are often necessary in HD cancer patients. These adaptations have to be carefully carried out to optimize drug exposure, ensure efficacy and reduce the risk of side-effects.

引用

页码：1395 / 1403

页数：9

共 77 条

[1] A PHASE-I CLINICAL, PLASMA, AND CELLULAR PHARMACOLOGY STUDY OF GEMCITABINE [J].

ABBRUZZESE, JL ;

GRUNEWALD, R ;

WEEKS, EA ;

GRAVEL, D ;

ADAMS, T ;

NOWAK, B ;

MINEISHI, S ;

TARASSOFF, P ;

SATTERLEE, W ;

RABER, MN ;

PLUNKETT, W .

JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (03) :491-498

[2] Pharmacodynamic study of the saltz regimen for metastatic colorectal cancer in a hemodialyzed patient [J].

Akiyama, Shinichiro ;

Nakayama, Hidetsugu ;

Takami, Hiroya ;

Gotoh, Hiromichi ;

Gotoh, Yoshikazu .

CHEMOTHERAPY, 2007, 53 (06) :418-421

[3]

Balat O., 1996, European Journal of Gynaecological Oncology, V17, P232

[4] Should low-dose methotrexate therapy be prescribed to dialysis patients? [J].

Basile, C ;

Montanaro, A ;

Semeraro, A .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 (03) :530-531

[5] High dose single-agent paclitaxel in a hemodialysis patient with advanced ovarian cancer: a case report with pharmacokinetic analysis and review of the literature [J].

Baur, M. ;

Fazeny-Doerner, B. ;

Olsen, S. J. ;

Dittrich, C. .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2008, 18 (03) :564-570

[6]

BLEYER WA, 1978, CANCER-AM CANCER SOC, V41, P36, DOI 10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO

[7]

2-I

[8] Severe methotrexate intoxication in a haemodialysis patient treated for rheumatoid arthritis [J].

Boulanger, H ;

Launay-Vacher, V ;

Hierniaux, P ;

Fau, JB ;

Deray, G .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (05) :1087-1087

[9] CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION [J].

CALVERT, AH ;

NEWELL, DR ;

GUMBRELL, LA ;

OREILLY, S ;

BURNELL, M ;

BOXALL, FE ;

SIDDIK, ZH ;

JUDSON, IR ;

GORE, ME ;

WILTSHAW, E .

JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1748-1756

[10]

Cengiz Kuddusi, 2002, International Urology and Nephrology, V33, P121

← 1 2 3 4 5 6 7 8 →